Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Duchenne Muscular Dystrophy Drugs Market Growth in 2025?
In recent times, there has been a significant expansion in the duchenne muscular dystrophy (DMD) drug market. The market size, which stands at $2.83 billion in 2024, is projected to increase to $3.23 billion in 2025, signifying a compound annual growth rate (CAGR) of 14.2%. Factors contributing to this growth during the historic time frame include advanced diagnostic capabilities, an increase in patient registries and data collection, high demand, an expanding line of clinical-stage therapies, and an upsurge in regulatory incentives.
What Is the Forecast for the Duchenne Muscular Dystrophy Drugs Market Size Through 2029?
The market size for drugs treating Duchenne Muscular Dystrophy (DMD) is poised for rapid expansion in the coming years, anticipated to reach $5.42 billion in 2029, at a compound annual growth rate (CAGR) of 13.8%. Several factors contributing to this growth include an increase in early-stage biotechnology companies entering the market, a rise in real-world evidence and post-marketing data, heightened health spending, expanding demand for early intervention methods, and an increase in off-label corticosteroid use. Key trends propelling this growth further during the forecast period include the booming innovation in biotechnology, the maturing integration of digital health and wearable technology, heightened interest in personalized and mutation-specific treatments, as well as advancements in gene therapy and CRISPR technology.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24213&type=smp
What are the Key Market Players in Duchenne Muscular Dystrophy Drugs Market and How They’re Evolving?
Major companies operating in the duchenne muscular dystrophy drugs market are Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb, Novartis AG, GSK plc, Eli Lilly and Company, Aurobindo Pharma Limited, Italfarmaco S.p.A, Sarepta Therapeutics Inc., PTC Therapeutics Inc., FibroGen Inc., Wave Life Sciences Ltd., Solid Biosciences Inc., NS Pharma, Capricor Therapeutics Inc., Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc., EspeRare Foundation, Satellos Bioscience Inc.
What Are the Primary Growth Drivers in the Duchenne Muscular Dystrophy Drugs Market?
The expansion of personalized medicine is set to stimulate the advancement of the Duchenne muscular dystrophy (DMD) drugs market in the future. Adopted as an approach in the medical field, personalized medicine applies treatments adjusted to each patient’s genetic, environmental, and lifestyle attributes, with the aim to maximize results and enhance care. With breakthroughs in genomic technologies, there is more demand for personalized medicine as it facilitates precise detection of genetic disparities and customized treatments for individuals. This aspect benefits Duchenne muscular dystrophy (DMD) drugs as it propels the production of targeted therapies based on individual genetic patterns, making treatments more efficacious for patients. Focusing on distinct genetic mutations, it boosts drug development, betters treatment results, and elevates the overall care provided to patients. The Personalized Medicine Coalition (PMC), a nonprofit organization from the U.S, reported in February 2024 that the U.S. Food and Drug Administration (FDA) approved 26 novel personalized medicines in 2023, which was a considerable jump from the 12 approved in 2022. Thus, the Duchenne muscular dystrophy (DMD) drugs market is driven by the growth in personalized medicine.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24213&type=smp
What Are the Leading Segments in the Global Duchenne Muscular Dystrophy Drugs Industry?
The duchenne muscular dystrophy drugs market covered in this report is segmented –
1) By Drug Type: Exon Skipping Drugs, Corticosteroids, Gene Therapy, Other Drug Types
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) Exon Skipping Drugs: Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Other Exon Skipping Therapies
2) Corticosteroids: Prednisone, Deflazacort, Other Corticosteroids
3) Gene Therapy: Micro-dystrophin Gene Therapy, CRISPR/Cas9-Based Gene Editing, Stem Cell-Based Gene Therapy, Other Gene Therapies
4) Other Drug Types: Utrophin Modulators, Anti-Inflammatory Agents, Antisense Oligonucleotides, Myostatin Inhibitors, Other Supportive Therapies
What Are the Key Market Trends in the Duchenne Muscular Dystrophy Drugs Industry?
Leading corporations in the DMD drugs market are making efforts to develop groundbreaking technologies such as corticosteroids, as a way to enhance muscle power, decelerate disease advancement, and improve patient outcomes overall. Corticosteroids are a type of steroid hormones either naturally produced in the adrenal glands or created as medication to decrease inflammation and restrain the immune system. For example, in March 2024, Catalyst Pharmaceuticals, a biopharmaceutical firm based in the US, introduced AGAMREE (vamorolone) oral suspension 40 mg/mL. This FDA-approved treatment is utilized for treating Duchenne muscular dystrophy in patients who are two years old or older. AGAMREE is a corticosteroid that operates by suppressing inflammation and stabilizing muscle cell membranes, which aids in slowing the progression of the disease.
Access The Full Report Here:
What Is the Regional Outlook for the Duchenne Muscular Dystrophy Drugs Market?
North America was the largest region in the duchenne muscular dystrophy (DMD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the duchenne muscular dystrophy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/customise?id=24213&type=smp
This Report Delivers Insight On:
1. How big is the duchenne muscular dystrophy drugs market, and how is it changing globally?
2. Who are the major companies in the duchenne muscular dystrophy drugs market, and how are they performing?
3. What are the key opportunities and risks in the duchenne muscular dystrophy drugs market right now?
4. Which products or customer segments are growing the most in the duchenne muscular dystrophy drugs market?
5. What factors are helping or slowing down the growth of the duchenne muscular dystrophy drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model